Imagine growing a patient's own heart cells in a lab to fix a damaged heart without the body rejecting them. Right now, this is too expensive and unpredictable to do for everyone. This work uses smart bioreactors and AI to act like a high-tech kitchen that ensures every batch of cells is perfect and affordable.
Personalized heart cell therapies are currently too expensive and inconsistent for wide use. The lack of GMP-compatible, scalable manufacturing makes these treatments clinically unviable.
An AI-enhanced manufacturing platform featuring 300 mL stirred-tank bioreactors, digital twins for process stability, and genomic QC assays for cell triaging.
If you are a cell therapy manufacturer dealing with high production costs and unpredictable cell quality — this project developed an AI-driven manufacturing platform that stabilizes cell expansion and differentiation. This allows for high-density parallel production of patient-specific doses in 300 mL scale.
If you are a bioreactor hardware provider dealing with the need for closed-system GMP compliance — this project developed advanced stirred-tank bioreactor technology. This enables the production of numerous patient-specific doses in a standardized 300 mL scale.
If you are an AI software developer dealing with the lack of predictive quality control in biotech — this project developed digital twins and hybrid modelling. These tools link molecular profiles to phenotypic outcomes to triage unstable cell lines early.
It uses AI-powered predictive quality control, novel Sendai vectors for efficient reprogramming, and high-density parallel production in 300 mL bioreactors to make therapies more affordable.
Yes, the project focuses on a GMP-compatible manufacturing platform using stirred-tank bioreactors for parallel production of numerous patient-specific doses.
Based on available project data, the project develops AI-driven hybrid modelling, digital twins, and novel Sendai vectors, which are key technical assets for licensing in regenerative medicine.
The project aims for GMP-compatible manufacturing and is generating EMA-aligned documentation to ensure clinical viability in Europe.
The project runs from 2026-09-01 to 2030-08-31, with validation planned across two EU and one US site.
The consortium is well-balanced for translation, consisting of 8 partners across 7 countries. With a 25% industry ratio (including 2 SMEs), the project blends academic research from 4 universities and 2 research institutes with commercial expertise to ensure the GMP manufacturing platform is viable for the market.
Contact the Medizinische Hochschule Hannover regarding the GMP manufacturing platform
Contact us to identify licensing opportunities for the AI-driven cell quality control tools.
